Immunosuppression: Promises and failures

Journal of the Neurological Sciences

Volumn 259, Issue 1-2, 2007, Pages 74-78

  Oger, Joël ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Azathioprine; Clinical trials; Corticosteroids; Cyclophosphamide; Immunosuppression; Metotrexate; Mitoxantrone; Multiple sclerosis

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BETA INTERFERON; CLADRIBINE; CORTICOSTEROID; CORTICOTROPIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FINGOLIMOD; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INTERFERON; INTERFERON BETA SERINE; METHOTREXATE; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; PACLITAXEL; PREDNISONE; STEROID;

ACUTE HEPATITIS; ACUTE MYELOBLASTIC LEUKEMIA; ACUTE MYELOMONOCYTIC LEUKEMIA; ACUTE PSYCHOSIS; ALOPECIA; AMENORRHEA; ARTICLE; BLOATING; BLOOD PRESSURE; DRUG MEGADOSE; GINGIVA HYPERPLASIA; HEART ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEPATITIS; HIRSUTISM; HUMAN; HYPERTENSION; HYPOMANIA; IMMUNOSUPPRESSIVE TREATMENT; INSOMNIA; LEUKOPENIA; LIVER DYSFUNCTION; LOW DRUG DOSE; MULTIPLE SCLEROSIS; NAUSEA; NEPHROTOXICITY; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; URINARY TRACT INFECTION;

DRUG EVALUATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS;

EID: 34447279095     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2006.05.073     Document Type: Article

References (38)

1. Milligan N.M., Newcombe R., and Compston D.A. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. Neurol Neurosurg Psychiatry 50 5 (1987) 511-516
2. Filippini G., Brusaferri F., Sibley W.A., Citterio A., Ciucci G., Midgard R., et al. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev 4 (2000) CD001331 Art. No: CD001331, DOI: 10.1002/14651858
3. Barnes D., Hughes R.A., Morris R.W., Wade-Jones O., Brown P., Britton T., et al. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 349 9056 (1997) 902-906
4. Beck R.W., Cleary P.A., Trobe J.D., Kaufman D.I., Kupersmith M.J., Paty D.W., et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. N Engl J Med 329 24 (1993) 1764-1769
5. Whitham R.H., and Bourdette D.N. Treatment of multiple sclerosis with high-dose methylprednisolone pulse therapy. Neurology 39 1 (1989) 357
6. Zivadinov R., Rudick R.A., De Masi R., Nasuelli D., Ukmar M., Pozzi-Mucelli R.S., et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 7 9 (Oct 57 2001) 1239-1247
7. Aimard G., Girard P.F., and Raveau J. Multiple sclerosis and the autoimmunization process. Treatment by antimitotics. Lyon Med 2156 6 (1966) 345-352
8. Oger J., Cloarec L., Chatel M., and Sabouraud O. Are there any changes in CSF IgG levels in multiple sclerosis treated for long periods with an immunosuppressive agent (azathioprine). Nouv Presse Med 2 7 (1973) 443
9. Milanese C., La Mantia L., Salmaggi A., Campi A., Bortolami C., Tajoli L., et al. Double blind controlled randomized study on azathioprine efficacy in multiple sclerosis, preliminary results. Ital J Neurol Sci 9 (1988) 53-57
10. Ellison G.W., Myers L.W., and Mickey M.R. A placebo-controlled, randomized, double-masked, variable dosage clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis. Neurology 39 8 (1989) 1018-1026
11. British and Dutch Multiple Sclerosis Azathioprine Trial Group. Double-masked trial of azathioprine in multiple sclerosis. Lancet 2 (1988) 179-183
12. Sabouraud O., Oger J., Darcel F., Madigand M., and Merienne M. Long-term immunosuppression in multiple sclerosis: evaluation of treatments begun before 1972. Rev Neurol (Paris) 140 2 (1984) 125-130
13. Hommes O., and Weiner H. Results of an international questionnaire on immunosuppressive treatment of multiple sclerosis. Mult Scler 8 (2002) 139-141
14. Hommes O., and Weiner H. Clinical practice of immunosuppressive treatments in multiple sclerosis: results of a second international questionnaire. J Neurol Sci 223 (2004) 65-67
15. Sabouraud, O. and Oger, J. personal communication 1974.
16. Pulicken M., Bash C.N., Costello K., Said A., Cuffari C., Wilterdink J.L., et al. Optimization of the safety and efficacy of interferon beta 1b and azathioprine combination therapy in multiple sclerosis. Mult Scler 11 2 (2005) 169-174
17. Kappos L., Patzold U., Dommasch D., Poser S., Haas J., Krauseneck P., et al. Cyclosporine versus azathioprine in the long-term treatment of multiple sclerosis - results of the German multicenter study. Ann Neurol 23 1 (1988) 56-63
18. The Multiple Sclerosis Study Group. Efficacy of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. Ann Neurol 27 (190) 591-605.
19. Gonsette R.E., and Demnty L. Immunosuppression with cyclophosphamide (Endoxan) in multiple sclerosis. In: Hommes O.R., Mertin J., and Tourtellotte W.W. (Eds). Immunotherapies in multiple sclerosis (1986), Stuart Phillips Publications, Sutton 139-150
20. Drachman D.A., Paterson P.Y., Schmidt R.T., and Spehlmann R.F. Cyclophosphamide in exacerbations of multiple sclerosis. Therapeutic trial and a strategy for pilot drug studies. J Neurol Neurosurg Psychiatry 38 (1975) 592-597
21. Hauser S.L., Dawson D.M., Lehrich J.R., Beal M.F., Kevy S.V., Propper R.D., et al. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange and ACTH. N Engl J Med 308 (1983) 173-180
22. La Mantia L., Milanese C., Mascoli N., D'Amico R., and Weinstock-Guttman B. Cyclophosphamide for multiple sclerosis. Cochrane Database Syst Rev 4 (2005)
23. Likosky W.H., Fireman B., Elmore R., Eno G., Gale K., Goode G.B., et al. Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study. J Neurol Neurosurg Psychiatry 54 12 (1991) 1055-1060
24. Canadian Cooperative study. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group. Lancet 337 8739 (1991) 441-446
25. Smith D.R., Weinstock-Guttman B., Cohen J.A., Wei X., Gutmann C., Bakshi R., et al. A randomized blinded trial of combination therapy with cyclophosphamide in patients with active multiple sclerosis on interferon beta. Mult Scler 11 5 (2005) 573-582
26. Patti F., Reggio E., Palermo F., Fiorilla T., Politi G., Nicoletti A., et al. Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta. J Neurol 251 12 (2004) 1502-1506
27. Stuve O., Cepok S., Elias B., Saleh A., Hartung H.P., Hemmer B., et al. Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis. Arch Neurol 62 10 (2005) 1620-1623
28. Noseworthy J.H., Hopkins M.B., Vandervoort M.K., et al. An open-trial evaluation of mitoxantrone in the treatment of progressive MS. Neurology 43 7 (1993) 1401-1406
29. Bastianello S., Pozzilli C., D'Andrea F., Millefiorini E., Trojano M., Morino S., et al. A controlled trial of mitoxantrone in multiple sclerosis; serial MRI evaluation at one year. Can J Neurol Sci 21 3 (1994) 266-270
30. Edan G., Miller D., Clanet M., Confavreux C., Lyon-Caen O., Lubetzki C., et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomized multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 62 2 (1997) 112-118
31. Millefiorini E., Gasperini C., Pozzilli C., D'Andrea F., Bastianello S., Trojano M., et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 244 3 (1997) 153-159
32. Hartung H.P., Gonsette R., Konig N., Kwiecinski H., Guseo A., Morrissey S.P., et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomized, multicentre trial. Lancet 360 9350 (2002) 2018-2025
33. Goodin D.S., Arnason B.G., Coyle P.K., Frohman E.M., and Paty D.W. The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis. Neurology 61 (2003) 1332-1338
34. Millefiorini E., Gasperini C., Pozzilli C., D'Andrea F., Bastianello S., Trojano M., et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24 month clinical and MRI outcome. J Neurol 244 (1997) 153-159
35. Bastianello S., Pozzilli C., D'Andrea F., Millefiorini E., Trojano M., Morino S., et al. A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year. Can J Neurol Sci 21 (1994) 266-270
36. Edan G., Brassat D., and Clanet M. Safety profile of mitoxantrone in a cohort of 802 multiple sclerosis patients. Neurology 58 3 (2002) A168
37. Ghalie R.G., Edan G., Laurent M., Mauch E., Eisenman S., Hartung H.P., et al. Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology 59 (2002) 909-913
38. http://www.clinicaltrials.gov/ct/search.